MAPT and Alzheimer disease: P-tau217 is emerging as a robust and selective cerebrospinal fluid (CSF) [60, 61] and plasma [62] biomarker for tau pathology in AD and it was hypothesised that its selective accumulation in GVBs could provide the mechanistic explanation for increased presence in AD CSF and plasma [50].